Novo Nordisk, after facing novelty rejection twice for its patent application relating to AERx inhaled insulin delivery system, has sued Jon Dudas, the head of the US Patent & Trademark Office. Novo claims the USPTO authority has misinterpreted data, evidence and legislation and as a result of which Novo chooses to go to the court for presenting its evidence.
No comments:
Post a Comment